Alexion Pharmaceuticals (ALXN) Shares are Down -1.9%

Alexion Pharmaceuticals (ALXN) has risen sharply, recording gains of 0.8% in the past 4 weeks. However, the stock has corrected -1.9% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.01% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 3.24% and the fifty day Moving Average is 1.75%. Alexion Pharmaceuticals, Inc. has dropped 13.82% during the last three month period . Year-to-Date the stock performance stands at -32.04%.

Alexion Pharmaceuticals (ALXN) : The highest level Alexion Pharmaceuticals (ALXN) is projected to reach is $221 for the short term and the lowest estimate is at $140. The consolidated price target from 15 rating analysts who initiate coverage on the stock is $182.13 and the possibility the share price can swing is $23.38.


Alexion Pharmaceuticals (NASDAQ:ALXN): stock turned positive on Friday. Though the stock opened at $130, the bulls momentum made the stock top out at $131.6 level for the day. The stock recorded a low of $128.26 and closed the trading day at $129.63, in the green by 0.36%. The total traded volume for the day was 1,057,808. The stock had closed at $129.17 in the previous days trading.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.